We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Newly Developed Point-of-Care Hemoglobinometer Evaluated

By LabMedica International staff writers
Posted on 10 Dec 2014
Print article
Image: The TrueHb hemometer testing kit (Photo courtesy of the Indian Institute of Technology Delhi).
Image: The TrueHb hemometer testing kit (Photo courtesy of the Indian Institute of Technology Delhi).
Hemoglobin (Hb) concentration is routinely measured using automated analyzers, and although these counters are very accurate and reliable, they are expensive and too cumbersome for portability.

Portable hemoglobinometer can potentially provide the solution to the challenges as they are affordable, precise, and convenient and require only a tiny sample of capillary or venous blood, do not require any calibration and display digital results immediately.

Scientists at the Indian Institute of Technology Delhi (IITD; New Delhi, India) collected 200 hundred randomly selected venous blood samples, submitted for hemogram study at the Department of Hematology, All India Institute of Medical Sciences (New Delhi, India). The hemoglobin values of these samples were evenly spread. There were 67, 76, and 57 samples in the ranges of 3.4–8 g/dL, 8–12.5 g/dL, and 12.5–20 g/dL respectively.

The investigators evaluated the performance of the portable hemometer called TrueHb (New Delhi, India) developed by IITD, and compared it with an automated five-part hematology analyzer intended for in vitro diagnostic use in clinical laboratories, the Sysmex counter XT 1800i (Sysmex; Kobe, Japan). The two set of values were comparatively analyzed and the repeatability of the performance of TrueHb was also evaluated against Sysmex value.

The scatter plot of TrueHb values and Sysmex values showed linear distribution with positive correlations. The intraclass correlation (ICC) values between the two set of values was found to be very high. The mean difference in Bland–Altman plots of TrueHb values against the Sysmex values was found to be −0.02, with limits of agreement between -0.777 and 0.732 g/dL. Statistical analysis suggested good repeatability in results of TrueHb, having a low mean coefficient of variation (CV) of 2.22, against 4.44, that of Sysmex values, and 95% confidence interval of 1.99 to 2.44, against 3.85 to 5.03, that of Sysmex values.

The authors concluded that a strong positive correlation between the two measurements devices suggest that the newly developed hemometer, TrueHb, can potentially replace a pathology laboratory analyzer for the purpose of measuring hemoglobin in blood samples. Keeping the performance of TrueHb in view, the newly developed device exhibited the potential to become a dependable tool for healthcare providers for measuring and monitoring hemoglobin levels of patients in conventional healthcare setups as well as in field studies. The study was published on November 22, 2014, in the International Journal of Laboratory Hematology.

Related Links:
Indian Institute of Technology Delhi 
All India Institute of Medical Sciences
TrueHb



New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
HSV-1 Test
Herpes Simplex Virus 1 Test
New
3-Position Stirrer
ST-200 and SHP-200 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.